Citations

Showing 10 of 108104 citations.

Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory‐specific incidence and prognostic impact among 348 informative cases
Shah, Sahrish, Pardanani, Animesh , Elala, Yoseph, Patnaik, Mrinal M. , Reichard, Kaaren K. , Hanson, Curtis A. , Tefferi, Ayalew , Lasho, Terra L. , Patnaik, Mrinal , Tefferi, Ayalew , Ketterling, Rhett P.

Mayo Clinic

American Journal of Hematology | August 30, 2018 | Volume: 93 | Issue: 12 | Pages: 1461-1466

10.1002/ajh.25265 | PMID 30152525 Get It

AbstractThe World Health Organization (WHO) system lists five morphological categories of systemic mastocytosis (SM): indolent (ISM), smoldering, SM with an associated hematological neoplasm (SM‐AHN), aggressive (ASM) and mast cell leukemia (MCL). Recent studies have highlighted the prognostic importance of mutations in SM, including ASXL1, RUNX1, and SRSF2. In contrast, information on incidence of cytogenetic abnormalities in SM and their prognostic relevance, especially in the context of mutations, is limited. In the current study, we retrospectively reviewed the cytogenetic findings in 348 consecutive cases of SM (median age 59 years; 53% males); 41% constituted ISM, 45% SM‐AHN, 14% ASM and two cases of MCL. Karyotype was abnormal in 53 (15%) cases with incidences of 6% for ISM, 26% for SM‐AHN and 8% for ASM (P < .001); among SM‐AHN cases, abnormal karyotype incidences were 0% for SM‐AHN‐lymphoid and 28% for SM‐AHN‐myeloid (P < .001). Clinical correlative studies disclosed significant associations between abnormal karyotype and male sex (P = .002), age > 60 years (P = .04), thrombocytopenia (P < .001) and anemia (P < .001), but not with the presence of adverse mutations (P = .19). In univariate analysis, abnormal karyotype was associated with inferior survival (HR 3.0, 95% CI 2.0‐4.3), specifically confirmed for ASM (HR 4.9, 95% CI 1.1‐16.1) and SM‐AHN (HR 1.8, 95% CI 1.2‐2.7). Sample size adequacy allowed additional multivariable analysis in SM‐AHN‐myeloid, which disclosed independent prognostic contribution from adverse mutations (P = .003), anemia (P = .003) and thrombocytopenia (P = .001), but not from abnormal karyotype (P = .31). Our observations suggest that mutations are prognostically more relevant than karyotype in SM.
P2491Decreased AF burden with dynamic optimization of CRT pacing using the AdaptivCRT algorithm in heart failure patients: analysis of real-world patient data
Singh, Jagmeet , O’Donnell, David , Li, S, Cha, Y, Lunati, Maurizio

Mayo Clinic

European Heart Journal | August 30, 2018 | Volume: 39 | Issue: suppl_1 | Pages: No page available

10.1093/eurheartj/ehy565.p2491 Get It

Contending Worldviews in the Clinical Encounter: An Empirical Study of Complementary and Alternative Medicine Deliberations in Contemporary Medical Oncology
Kumbamu, Ashok , Geller, Gail , Leppin, Aaron L. , Fernandez, Cara, Tilburt, Jon C. , Koenig, Barbara A. , Leppin, Aaron

Mayo Clinic

The Journal of Alternative and Complementary Medicine | August 30, 2018 | Volume: 24 | Issue: 9-10 | Pages: 996-1002

10.1089/acm.2018.0200 | PMID 30156425 Get It

Sexual Health in Women
Kapoor, Ekta , Kling, Juliana M. , Kingsberg, Sheryl A. , Kling, Juliana M , Kapoor, Ekta , Faubion, Stephanie S.

Mayo Clinic

Journal of Women's Health | August 30, 2018 | Volume: 27 | Issue: 9 | Pages: 1082-1085

10.1089/jwh.2018.7326 | PMID 30153071 Get It

Composite Hydrogel Embedded with Porous Microspheres for Long-Term pH-Sensitive Drug Delivery
Liu, Xifeng , Fundora, Kevin A. , Zhou, Zifei , Lu, Lichun , Miller, Alan Lee, Miller, Alan Lee

Mayo Clinic

Tissue Engineering Part A | August 30, 2018 | Volume: 25 | Issue: 3-4 | Pages: 172-182

10.1089/ten.tea.2018.0071 | PMID 30152721 Get It

Current delivery of chemotherapy drugs to osteosarcoma is limited by the difficulties in overcoming the solid tumor microenvironment and the cardiotoxicity of doxorubicin (DOX). In previous work we found that phase separation could generate microspheres with high porosity. In this study, we applied these phase-separated porous microspheres as carriers for long-term anticancer drug delivery. Novel poly(propylene fumarate)- co -poly( l -lactic acid) microspheres incorporating DOX were fabricated by thermally induced phase separation. Following embedding into oligo(poly[ethylene glycol] fumarate) hydrogel, the composite system showed prolonged and pH-responsive release of DOX. In vitro cytotoxicity study using osteosarcoma 143B cells showed substantial long-term cytotoxic effects for up to 30 days. As a result, the DOX drug delivery hydrogel developed in this work may have significant potential as a long-term and localized chemotherapy device that would be sensitive to the acidic microenvironment of osteosarcoma and other cancers. Impact Statement A composite hydrogel embedded with porous microspheres fabricated by phase separation methods was developed and showed excellent long-term anticancer drug delivery capability to cancer cells.
Mutations and karyotype predict treatment response in myelodysplastic syndromes
Idossa, Damé , Finke, Christy M. , Patnaik, Mrinal M. , Pardanani, Animesh , Gangat, Naseema , Tefferi, Ayalew , Lasho, Terra L. , Patnaik, Mrinal , Gangat, Naseema , Tefferi, Ayalew , Ketterling, Rhett P.

Mayo Clinic

American Journal of Hematology | August 29, 2018 | Volume: 93 | Issue: 11 | Pages: 1420-1426

10.1002/ajh.25267 | PMID 30152885 Get It

Abstract We examined the influence of mutations and karyotype on conventional treatment response, specifically hematological improvement in anemia, in primary myelodysplastic syndromes (MDS). Cytogenetic and next generation sequencing (NGS)‐derived mutation information was available in 357 patients (median age 74 years; 70% males); the revised international prognostic scoring system risk distribution was very high in 11%, high 15%, intermediate 17%, low 40% and very low 16%. At least one mutation was detected in 81% of patients; most frequent were SF3B1 (32%), ASXL1 (27%), TET2 (24%) and U2AF1 (15%). At median follow‐up of 24 months, treatment with hypomethylating agents (HMAs) was documented in 121 (34%) patients, lenalidomide (LEN) in 55 (15%), and erythropoiesis stimulating agents (ESAs) in 136 (38%). ASXL1 mutations adversely affected response to HMAs (27% vs 48%; P = 0.02) and LEN (9% vs 43%; P = 0.04), but not ESAs ( P = 0.6). LEN response was also adversely affected by U2AF1 mutations (0% vs 42%; P = 0.02) and high risk karyotype (0% vs 41% in intermediate vs 47% in low risk; P = 0.01). Patients with SF3B1 mutations were more likely to respond to LEN (56% vs 27%; P = 0.04). Contrary to previous reports, we found no association between TET2 mutations and HMA treatment response (40% vs 41%; P = 0.9), even in the absence of ASXL1 mutations ( P = 0.4).We conclude that ASXL1 mutations in MDS predict inferior response to treatment with both HMAs and LEN; response to LEN was also compromised by U2AF1 mutations and high risk karyotype; SF3B1 mutations identified patients likely to respond to LEN.
P4540Comparison of right and left ventricular myocardial stiffness in patients with pulmonary hypertension and impact on outcomes
Anupraiwan, Orawan, Petrescu, Ioana, Tunhasiriwet, Anusith, Krittanawong, Chayakrit , Pislaru, Cristina , Pislaru, Cristina , Ionescu, Filip , Pislaru, Sorin V. , Pellikka, Patricia A. , Kane, Garvan C.

Mayo Clinic

European Heart Journal | August 29, 2018 | Volume: 39 | Issue: suppl_1 | Pages: No page available

10.1093/eurheartj/ehy563.p4540 Get It

Trichotillomania (hair pulling disorder): Clinical characteristics, psychosocial aspects, treatment approaches, and ethical considerations
França, Katlein , Kumar, Anagha , Castillo, David , Jafferany, Mohammad , Neto, Marcelo Hyczy da Costa, Damevska, Katerina , Wollina, Uwe , França, Katlein , Wollina, Uwe , Castillo, David, Lotti, Torello

Mayo Clinic

Dermatologic Therapy | August 29, 2018 | Volume: 32 | Issue: 4 | Pages: e12622

10.1111/dth.12622 | PMID 30152568 Get It

P892Functional tricuspid regurgitation in reduced ejection fraction heart failure: prevalence, determinants, and independent prognostic impact
Antoine, Clémence , Thapa, Prabin , Michelena, H., Benfari, Giovanni , Miller, Wayne L. , Nkomo, Vuyisile T. , Enriquez‐Sarano, Maurice

Mayo Clinic

European Heart Journal | August 29, 2018 | Volume: 39 | Issue: suppl_1 | Pages: No page available

10.1093/eurheartj/ehy564.p892 Get It

Therapeutic Efficacy of Vitamin D in Experimental c-MET‐β-Catenin-Driven Hepatocellular Cancer
Matsuda, Akiko , Ishiguro, Kaori, Yan, Irene K. , Patel, Tushar

Mayo Clinic

Gene Expression | August 29, 2018 | Volume: 19 | Issue: 2 | Pages: 151-159

10.3727/105221618x15355518848281 | PMID 30157994 Get It

Aberrant activation of β-catenin signaling is frequently observed in hepatocellular cancer. Although Wnt/β-catenin signaling can be targeted by vitamin D, therapeutic use of vitamin D for this purpose is not currently established. We evaluated the therapeutic use of vitamin D or its analogs using a synthetic transgenic mouse of hepatocarcinogenesis induced by mutant β-catenin, and MET overexpression in which 75% of mice develop well-differentiated HCC within 8 weeks in the absence of fibrosis. Vitamin D receptor expression was similar in both tumoral and nontumoral tissue. There was no significant difference in overall survival, or in tumor progression assessed by imaging, biochemical, or tumor cell burden assessments in mice receiving a vitamin D-supplemented diet containing 12.0 IU VD/g (HVD) compared with a standard diet (SD) containing 2.3 IU VD/g. Furthermore, systemic treatment with calcitriol [vitamin D analog 1α,25(OH) 2 D 3 ] or EB1089 (synthetic vitamin D analog) by intraperitoneal injection for 4 weeks prolonged median survival but did not increase overall survival compared with controls. Although tumor formation was delayed in males compared with that in females, there was no difference in overall survival between males and females. In conclusion, although 1α,25(OH) 2 D 3 is reported to inhibit β-catenin signaling, as well as proliferation, migration, and differentiation in cancer cells, neither dietary supplementation with vitamin D nor treatment with vitamin D analogs altered the formation or growth of HCC associated with β-catenin activation. These results conclusively demonstrate the lack of utility of targeting vitamin D for therapy of HCC in this setting.